Key points are not available for this paper at this time.
The constant demand for eco-friendly methods of synthesizing complex organic compounds inspired researchers to design and develop modern, highly efficient heterogeneous catalytic systems. Herein, In-HCPCP metal–organic framework (SRMIST–1), a heterogeneous Lewis acid catalyst containing less toxic indium and eco-friendly robust cyclotriphosphazene and exhibiting notable chemical and thermal stability, durable catalytic activity, and exceptional reusability was produced through the reaction between indium (III) nitrate hydrate and hexakis (4-carboxylatophenoxy) -cyclotriphosphazene. In the SRMIST–1 structure, secondary building units InO7 are assembled by a connection of η2- and η1-carboxylic oxo atoms from different HCPCP ligands, forming a three-dimensional network. The occurrence of regularly distributed In (III) sites in SRMIST–1 confers superior reactivity on the catalyst toward the synthesis of 2, 3-dihydroquinazolin-4 (1H) -ones and 3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-1, 1-dioxides by the cyclization reaction of 2-aminobenzamides and 2-aminobenzenesulphonamides with aldehydes under optimized reaction conditions, respectively. The notable features of this method include broad functional group compatibility, low catalyst loading (1–5 mol %), mild reaction conditions, easy workup procedures, good to excellent reaction yields, ethanol as a green solvent, reusability of the catalyst (five cycles), and economic attractiveness, which is mainly due to sustainability of SRMIST–1 as a reusable green catalyst. Our findings demonstrate that the highly reactive and reusable green catalyst finds widespread applications in medicinal chemistry.
Jeevananthan et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: